ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY

Jay Shavadia,Yinggan Zheng,Jennifer B. Green,Paul W. Armstrong,Cynthia Westerhout,Darren K. McGuire,Matthew T. Roe,J.H. Cornel,R R Holman,Eric D. Peterson

ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY

2019

Jay Shavadia
Yinggan Zheng
Jennifer B. Green
Paul W. Armstrong
Cynthia Westerhout
Darren K. McGuire
Matthew T. Roe
J.H. Cornel
R R Holman
Eric D. Peterson

The secondary prevention effects of beta-blocker therapy (BBT) in type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) are unclear. Using an inverse probability of treatment-weighted Cox proportional hazards model, we examined the association between baseline BBT and

Keywords:

Proportional hazards model
Type 2 diabetes
Beta blocker
Cardiology
Atherosclerotic cardiovascular disease
Medicine
Internal medicine
Diabetes mellitus
cardiovascular outcomes
beta blocker therapy
in patient
secondary prevention

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations